英国国家注册研究中符合纤维肌痛标准的轴性脊柱关节炎患者的共病情况与特征
该研究基于英国BSRBR-AS注册队列,纳入1504例符合ASAS标准的轴性SpA患者,其中20.7%符合2011年纤维肌痛研究标准。符合FM标准的患者疾病活动度、功能、整体严重度和生活质量显著更差,情绪障碍和疲劳更常见,工作能力受损约一半工作时间,但FM与CRP升高及多数关节外表现无关,与接受生物制剂治疗的可能性更高相关。
要点
- 轴性SpA患者中约五分之一符合纤维肌痛研究标准。
- 符合FM标准者疾病活动度、功能和生活质量显著更差。
- FM标准与CRP升高无关,但与接受生物制剂治疗可能性更高相关。
核心结论
- 符合纤维肌痛标准的轴性SpA患者约占五分之一,其疾病活动度、功能、整体严重度和生活质量显著更差,情绪障碍和疲劳更常见,工作能力受损约一半工作时间。
- 符合FM标准与CRP升高或多数关节外表现无关,但与接受生物制剂治疗的可能性更高相关。
- 针对这部分患者未被满足的临床需求开发管理方法应成为研究优先事项。
研究设计与样本
- 研究基于英国风湿病学会强直性脊柱炎生物制剂注册(BSRBR-AS),从英国83个中心前瞻性招募患者。
- 所有患者均需符合ASAS轴性SpA标准,分为新开始生物制剂治疗队列和未接受过生物制剂治疗队列,均前瞻性随访。
- 当前分析纳入1504例注册患者(68%为男性),基线及随访时记录临床信息,患者完成2011年FM研究标准及疾病活动度和工作影响评估。
主要发现
- 1504例 eligible 患者中311例(20.7%)符合2011年FM研究标准。
- 符合改良纽约强直性脊柱炎标准的患者FM患病率为19.7%,符合ASAS影像学标准但不符合改良纽约标准者为25.2%,仅符合ASAS临床标准者FM患病率较低为9.5%。
- 符合FM标准的患者报告疾病活动度、功能、整体严重度评分和生活质量显著更差,中度或重度情绪障碍及临床重要疲劳的可能性更高。
- 符合FM标准的患者报告约一半工作时间存在工作能力受损。
- 符合FM标准与CRP水平升高或多数关节外表现无关,但与接受生物制剂治疗的可能性更高相关。
关键数值与推荐
- FM标准采用2011年纤维肌痛研究标准。
- 轴性SpA诊断采用ASAS标准,并区分改良纽约标准、ASAS影像学标准和ASAS临床标准。
- 符合FM标准者FM患病率在改良纽约标准组为19.7%,ASAS影像学但非改良纽约标准组为25.2%,仅ASAS临床标准组为9.5%。
临床怎么用
- 对轴性SpA患者应评估是否符合纤维肌痛研究标准,尤其疾病活动度、功能和生活质量差而CRP不高者。
- 符合FM标准的轴性SpA患者情绪障碍和疲劳更常见,工作能力受损明显,需综合管理。
- 符合FM标准与接受生物制剂治疗可能性更高相关,临床决策时应考虑FM共病对治疗选择的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the proportion of patients with axial spondyloarthritis (SpA) in a UK national biologics registry who met criteria for fibromyalgia (FM), and to delineate the characteristics of these patients. METHODS: Two cohorts of patients are prospectively recruited from across 83 centers in the UK for the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS). All patients are required to meet Assessment of SpondyloArthritis international Society (ASAS) criteria for axial SpA. Patients are either newly starting biologic therapy (biologics cohort) or are naive to treatment with biologic agents (non-biologics cohort) at the time of recruitment, and all patients are followed up prospectively. At recruitment and follow-up, clinical information and measurements are recorded while patients complete the 2011 research criteria for FM and assessments of the level of disease activity and work impact. RESULTS: Of the patients registered in the BSRBR-AS, 1,504 (68% male) were eligible for the current analysis, of whom 311 (20.7%) met the 2011 research criteria for FM. Prevalence of FM was similar between patients who fulfilled the modified New York criteria for AS (19.7%) and those who fulfilled ASAS imaging criteria but not the modified New York criteria (25.2%); however, among those who fulfilled only the ASAS clinical criteria, the prevalence of FM was lower (9.5%). Patients who met FM criteria reported significantly worse disease activity, function, global severity scores, and quality of life, and were more likely to have moderate or severe levels of mood disorder and clinically important fatigue. Patients who met FM criteria reported experiencing work impairment around half their working time. Meeting FM criteria was not related to elevated C-reactive protein levels or most extraspinal manifestations, but was associated with a higher likelihood of having received biologic therapy. CONCLUSION: Developing management approaches that would address the significant unmet clinical needs of the 1 in 5 patients with axial SpA who meet criteria for FM should be a research priority.
引用
- Macfarlane GJ, Barnish MS, Pathan E, et al. Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register. Arthritis Rheumatol. 2017. PMID: 28622461. doi:10.1002/art.40185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。